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Introduction
Glycosylation, i.e. protein decoration with carbohydrates or glycans is the most diverse form of protein posttranslational modifications (PTM) and can provide a huge degree of glycan variations to the protein backbones. These various glycosylated molecules are synthesized mainly in the endoplasmic reticulum and Golgi via reactions involving sugar nucleotide synthases and their transporters, glycosyltransferases, glycosidases and other sugar-modifying enzymes. Branched N-linked and O-linked glycan chains modify glycoproteins, while proteoglycans are modified with linear glycans. The biological role of glycans has been linked to a broad variety of phenomena such as cell growth and development, malignant tumor growth, differentiation and metastasis, within several steps of immune response, microbial-host interactions and intercellular adhesion (Ebnet et al. 2004 , Ley and Kansas 2004 , Lowe 2003 , 4 Rosen 2004 , Rudd et al. 2004 , von Andrian and Mempel 2003 .
Descriptive analysis of human glycoconjugates began with the discovery of lectins in the late 1940's and their use in ABO blood typing (Renkonen 1948, Morgan and Watkins 2000) . Lectins and later also glycans specific antibodies have revealed a great amount of circumstantial evidence of various glycoproteins on cell surfaces, their tissue distributions as well as expression patterns at sites of diseases such as inflammations (Kannagi 2002 , Renkonen et al. 2002 , Rosen 2004 , Uchimura and Rosen 2006 .
Identification of glycoproteins has relied on the analysis of non-glycosylated peptides.
Traditionally protein glycosylation analysis has been performed with enzymatically (Takahashi et al. 2003) or chemically (Yosizawa et al. 1966 ) released glycans, which have been analyzed with various mass spectrometry approaches (Barr et al. 1991 , Duffin et al. 1993 , Mock et al. 1991 and manual or automated interpretation of the spectra (Cooper et al. 2001 , Mizuno et al. 1999 ). There are several software tools for analyzing released glycans. Cartoonist (Goldberg et al. 2005 ) is the simplest and thus most applicable in high-throughput analysis of these and uses solely MALDI ionization and precursor ion masses for the calculation of potential glycan compositions. More advanced software, such as STAT (Gaucher et al. 2000) , FragLib , and StrOligo (Ethier et al. 2002) use MS 2 and OSCAR (Lapadula et al. 2005) MS n data to match the glycan structures, but still lack the information of glycosylation sites on the protein backbone. GlycoMod (Cooper; Gasteiger et al. 2001 ) is the first software tool for the analysis of the glycan composition in the glycopeptide. Here the mass of the peptide moiety 5 needs to be previously known as the analysis is based on the total mass of the glycan. Sweet
Substitute (Clerens et al. 2004 ) uses another approach and generates theoretical N-glycopeptide CID spectra for one or few known glycopeptides and compares the empirical spectrum against them. Recently high-throughput methods for the analysis of occupied glycosylation sites on glycopeptides were published (Sun et al. 2007 , Zhang et al. 2003 , where after conjugation of glycopeptides to beads, the glycans were released and the asparagines modified to aspartic acid on the peptides could be identified. Regardless of many present tools developed so far none of them is able to determine the components of glycopeptide when glycan and peptide moieties are unknown.
We describe here our novel automated in silico workflow for the glycoprotein analysis. The workflow analyzes N-glycopeptide mass spectra to determine concomitantly their amino acid sequences and glycosylations in a high-throughput manner (Figure 1 ). The main target is unknown glycoprotein mixtures, but as a proof of principle we show first the analysis of purified human plasma serotransferrin.
Results and discussion

Analysis of glycoforms of human serotransferrin
Trypsinization of human serotransferrin leaves the amino acid backbones long enough for identification against database search whereas other methods such as pronase or chemical 6 cleavage yield too short peptides for identification from unknown mixtures. Non-glycosylated peptides represent >95 % of the mixture and suppress the ionization of the few glycopeptides.
The presence of several glycovariants from the same glycosylation site reduces the molar ratio of unique glycopeptides further and thus the glycopeptides need to be enriched. For that we used a size-exclusion column (Alvarez-Manilla et al. 2006) , but also other methods such as HILIC (Zhang et al. 1998) and multidimensional lectin chromatography (Fu and van Halbeek 1992 , Hirabayashi and Kasai 2002 , Qiu and Regnier 2005 have been used by others and us. The specimens were first acquired in the LC-MS mode for quantitation (Zhu et al. 2000) followed by LC-MS 2 in the stopflow mode (Davis et al. 1995 , Vissers et al. 2002 to ensure the highest possible quality of the spectra. The MS 2 fragmentation was carried out with a wide range of collision energies (10 -70 eV) to ensure a suitable range of collision energy for fragmenting both peptide and glycan moieties (Jebanathirajah et al. 2003) . This yielded approximately 10 GB of raw data containing ~10 000 MS 2 spectra, out of which only a subset meeting the following three criteria was selected for further analysis: i) the glycan marker ions, 204 m/z (HexNAc), 292 m/z (NeuAc), 366 m/z (HexHexNAc), or 657 m/z (HexHexNAcNeuAc) are present (Carr et al. 1993) , ii) ions of fragmented glycan still attached to the intact peptide moiety are present and iii) the charge of the precursor ion can be determined. After this selection the spectra were deconvoluted with MaxEnt3 algorithm (Waters) to single charge monoisotopic spectra and were extracted to the Medicel Integrator software platform. From the 300 extracted spectra the ones representing same precursors (Δ mass < 0.1 Da) were combined and 150 spectra entered to the next analytical step.
Automated in silico workflow for the glycoprotein analysis
Amino acid sequence
The analysis of the glycopeptide spectra began with determination of their peptide sequences.
For this we first generated a database of the human UniProt (Wu et al. 2006 ) FASTA sequences, in silico trypsinized it with maximum of 2 miscleavages and selected the sequences containing the N-glycosylation consensus sequence (Bause and Legler 1981, Marshall 1974 ) (Supplement Table 1 ). These 440 000 in silico tryptic peptides were fragmented and their b-and y-ion series were matched to the 150 measured glycopeptide spectra obtained in the MS 2 fragmentation experiments (Conboy and Henion 1992) (Figure 2a ). Unlike in the classical peptide analysis the total mass of the precursor ion could not be used to filter peptides as we had unknown combinations of amino acid sequences and glycan decorations. Therefore we required that the MS 2 spectrum contained a peptide+HexNAc peak, which is known to be intensive in glycopeptide spectra (Ritchie et al. 2002) . For each precursor there were on average 800 (range 0-6000) putative peptide interpretations fulfilling this requirement. After matching the observed fragmentation peaks against the library of the 800 in silico peptides, 50 best scoring amino acid sequences for each spectrum were stored for further analysis (Supplement Table 2 ). However the presence of the peptide+HexNAc in the spectra is not obligatory, although its presence limits the number of putative solutions. Our protein identification within this software analysis can also be executed from either an identified peptide or only b-and y-ions.
N-glycan composition
The compositions of the putative N-glycan decorations on the given glycopeptide were 8 calculated based on the mass differences of the observed glycopeptide mass and the masses of the putative amino acid backbones. Combinations of four monosaccharides (Hex, HexNAc, DeoxyHex and NeuAc) and one optional formylation for each (artificial modification from the sample and LC buffers) (Gottlieb et al. 1940) were used to generate possible compositions. Few limiting rules were applied to filter out the most unlikely compositions (Cooper; Gasteiger et al. 2001) . The average number of putative glycan compositions for each spectrum was 50 with a ±0.2 Da precursor mass tolerance (Supplement Table 3 ). To sort out the most reliable explanations from this pool of interpretations the putative glycan compositions were scored with the observed glycopeptide spectra (Figure 2b ). The scoring was done by matching all combinations of glycan and intact peptide+glycan fragments, which may be produced from the unknown glycan structures having the glycan composition and the N-glycan core structure. For each spectrum 20 peptide+glycan compositions with highest sum of peptide and glycan composition scores were stored for further analysis (Supplement Table 4 ).
Statistical validation of peptide matches of the glycopeptide interpretations
When analyzing samples, that are mixtures, the confidence of the interpretations should be determined. A target-decoy approach (Beausoleil et al. 2006 ) was used to estimate the true positive rate of matched peptides. To generate the decoy database the amino acid sequences of the 440 000 in silico glycopeptides were reversed. The amino acid sequence and glycan analysis were performed for all the 150 spectra using the target and decoy glycopeptide databases. The peptide score of the best matching glycopeptides of each spectrum was used as the filtering variable and the score cut off was selected so that the number of decoy hits indicated 90 % level of true positives.
De novo N-glycan structures
At the final step, for each glycan composition, a set of de novo glycan structures (without linkage information), which matched best with the measured spectrum were generated. As the number of unique structures with a given composition can be huge, not all structures were generated, but were searched with our novel Branch and Bound type algorithm. The algorithm iteratively grows a population of N-glycan structures, filters out structures, which match least to measured spectrum, until structures have grown to target composition. Theoretical spectra were generated using fragments resulting from glycosidic cleavages. Cross ring cleavages were not included as they are not visible in protonated spectra (Harvey 2001) . The method used is true de novo, it does not use a database of known structures, only N-glycan core structure (with and without bisecting HexNAc) was given as input. However, some limiting factors like maximum number of branches were used. Finally, for each spectrum up to 30 glycopeptide structures with highest sum of peptide and structure scores were stored ( Figure 2c and Supplement Table 5 ).
This list is the final result, which can be achieved with the automatic workflow. Automatic selection of only one identified or undoubtedly best matching structure for each spectrum proved to be difficult. Typically dozen of structures from the original ~10 9 theoretical glycopeptide search space matched almost equally well. The reason is that the theoretical spectra of various isomeric structures can be very similar or even identical. At most cases the final selection (if necessary) have to be done based on other biological information.
Our analysis of human serotransferrin showed that we could interpret 62 out of the 150 glycopeptide spectra with the 90 % confidence level of identified peptides within a few hours. 31
individual glycopeptides represented the N431 site, 6 glycopeptides the N491 site and 19 glycopeptides the N631 site (Table 1) . Altogether the structures, i.e. not on ly the composition but also the sequence of the glycans, could the determined for 45 out of the 62 interpreted spectra (Supplement Table 6 ).
Validation of the results
For further proof we also isolated one of the glycopeptides (m/z = 1227.691, z = 3 ) with offline HPLC and released its N-glycans with PNGase F. The glycans were analyzed with nanoESI- studies. We fragmented the major glycan decorating serotransferrin and known from previous literature to the b-, c-and y-, z-ion series in silico and compared these to the measured data. We could assign all the theoretical fragments in our the MS 2 spectrum (Figure 3, Supplement Table   7 ). Concomitantly our automated workflow also provided the same result (spectrum 4 in Table1), representing m/z = 1227.691.
Glycopeptide relative quantitation with LC-MS
In addition to the LC-MS 2 stopflow analysis we acquired an LC-MS spectrum of the original tryptic digest for relative quantitation of different glycopeptides and glycosylation sites. The acquisition was done from the sample prior to size exclusion chromatography in order to 11 preserve the original ratios of glycosylation sites. Not all the precursors were found as expected, because in the size exclusion chromatography glycopeptides are enriched compared to the original digest. Abundances of not detected glycopeptides in the LC-MS were assumed to be insignificant as in the first place they had to be enriched to be acquired in the stopflow experiment. The relative quantities of the glycosylation sites were: N432 67 %, N491 1 % and N630 32 %.
Analysis of glycoforms of human plasma
When applying this in silico analysis method to human plasma specimen we could identify 80 spectra, i.e. identify 80 glycopeptides with their amino acid sequence and concomitantly their glycan compositions (Table 2) followed by structure analysis (Supplement Table 8 ). The execution of the workflows takes only a few hours and thus shows the dramatic increase on pace of the glycopeptide analysis. Previously it has not been possible to go through thousands and thousands of optional glycopeptide interpretations and to validate them automatically.
The aim of the last part of this work was to identify glycoproteins via their respective glycopeptides from a very complex mixture of glycoproteins where the manual analysis is not possible. To our knowledge no one has been able to come even close with glycoprotein analysis when starting to analyze a complex mixture as we here.
Taken together we describe here our novel automated in silico workflow for the rapid analysis of un purified glycoproteins or even complex mixtures of glycoproteins. First in our analysis with 12 purified serotransferrin out of over 10 9 theoretical glycopeptide combinations our automated workflow generated 10 5 putative interpretations for 150 glycopeptide spectra. 62 spectra (40 %) yielded statistically valid data of a) amino acid sequence, b) glycan composition and c) glycan structures. We identified 62 individual glycopeptide compositions representing three different glycosylation sites. The most abundant and variable in glycan structures was the glycosylation site N432. Secondly we could directly apply this analysis workflow also to very complex mixture of human plasma glycoproteins and detect some 80 various glycopeptides with one in silico workflow execution. These examples emphasize the great power of in silico approaches to the interpretation of mass spectrometry data for the analysis of glycopeptides structures.
Materials and methods
Plasma processing
The human blood was collected to the 3.5 ml Venosafe lithium heparine gel (VF-054SAHLW)
tubes, cooled at room temperature for 15 minutes, centrifuged for 10 minutes 1200 g at room temperature. The plasma was aliquoted and stored in -80 °C for further use. In the preparation of plasma bulk and low abundance protein fraction was used Agilent Technologies, Inc, (Palo Alto, USA) Multiple Affinity Removal System HPLC column 4.6 mm x 100 mm (5185-5985) as stated in the manufacturer's instructions.
Digestion of proteins
Plasma bulk and low abundance protein fractions and human serotransferrin from Sigma-Aldrich Ltd, (MO, USA).
(1 mg of protein) were trypsin digested, reduced and alkylated (22).
Size exclusion chromatography of protein digest
Glycopeptides were enriched from protein digest using size exclusion chromatography (23). In brief, 1 nmol of human serotransferrin, plasma low abundant or bulk protein digest was injected to Superdex Peptide 10/300 GL column, 2.1 mm x 250 mm (GE Healthcare Bio-Sciences) and the peptides were eluted isocratically at 0.1 ml/min with 0.1% trifluroacetic acid. 0.1 ml fractions were collected and vacuum dried.
Mass spectrometry
The peptide and glycopeptide spectra were acquired with Micromass Ltd (Manchester, UK) Q-TOF Ultima Global mass spectrometer using variable flow nano high-pressure liquid chromatography with Waters Ltd, (MA, USA) Ltd CapLC system. The analytical column used was LC Packings (Amsterdam, NL) 25 cm long PepMapC18 with 75 µm diameter. The ESI spectra were acquired in the positive mode during 600 minutes gradient 5% B (95% acetonitrile and 0.1% formic acid) to 30 % B (buffer A was 5% acetonitrile, 0.1% formic acid) and acquisition range was set to 800-1600 m/z in MS Survey and 100-4000 m/z in MS 2 mode.
Spectra were collected in data dependent acquisition fashion including charge states +2 -+6.
We applied a series of collision energies between 10-70 eV in the CID experiments. The 
Relative quantitation of human serotransferrin glycopeptides.
Mass chromatograms for precursor ions of different glycoforms of transferrin glycopeptides were extracted from an LC/MS run of transferrin digest. Elution time for each precursor was determined and a combined spectrum was created from the mass chromatogram. The spectrum was deconvoluted using Masslynx 4.0 software and MaxEnt3 algorithm (Waters). Relative quantities of glycopeptides were calculated from deconvoluted peak intensities. Site specific relative quantities were calculated based on sum of intensities of the precursors assigned to be a glycopeptide containing one of three possible glycosylation sites independent of peptide sequence length and glycan composition.
N-Glycan release and analysis.
N-linked glycans were released from glycopeptide with PNGase F (Sigma-Aldrich, MO) in solution containing 20 % acetonitrile, 5 mM ammonium acetate and 50 mU/µl PNGase F. The released glycan was analyzed using Hypercarb column (Thermo Electron Corporation, MA) coupled to CapLC HPLC-system and mass spectrometer with nanoESI interface. Solvent A was 5 mM ammonium acetate and solvent B was 5 mM ammonium acetate in 80 % acetonitrile. The glycan was eluted from Hypercarb column using gradient of solvent B from 5 % to 50 % over 18 minutes. Mass of the glycan was determined by an LC/MS experiment. The glycan was fragmented with six collision energies (10-60 eV) in six consecutive LC/MS 2 experiments. The acquired fragmentation data was deconvoluted using MaxEnt3 algorithm (Waters) and analyzed further to obtain the glycan composition.
N-glycopeptide workflow
The in silico N-glycopeptide analysis workflow is a part of Medicel Integrator Protein Nglycosylation suite version 1.0 (www.medicel.com). Medicel Integrator is a modular software platform for biological and biomedical research and development. It connects all data to a relational database and enables continuous processes and solid tracking of data, from sample information and laboratory procedures to the in silico processes. The key applications used in this study are the laboratory information management system entitled Experiment and Workflow.
The latter is an application with graphical user interface for automated data analysis. Workflow implements client-server architecture, can run automatically consecutive tools and has a tool server cluster for tool execution. Medicel Integrator versions used were 1.1, 1.2 and 1.3.
The N-glycopeptide analysis workflow contained eight distinct tools (Supplement Figure 3) .
Tools used in analysis were coded with Java or with Matlab 6.5 (MathWorks Inc). Matlab tools were compiled to stand alone tools with Matlab Compiler 3.0 (MathWorks Inc).
1. Combine spectra. Deconvoluted input spectra where precursor mass difference was less than 10 mDa were combined as one spectrum and converted to Medicel mass spectrometry xml format. The combinations were done by adding 400 highest intensity peaks from different spectra to a single peak list. The idea of combination was to combine peaks from the same precursor, but with different collision energies to a single spectrum 2. Retrieve protein sequences UniProt (25) human proteins in FASTA format were retrieved from the Medicel data warehouse, which had UniProtKB version 2.5 integrated. Number of human protein entries was 44601. Each protein entry within Medicel data warehouse was sequence aligned for its uniqueness and given an unique Medicel identifier, which allowed it to be linked with other data domains such as genes and transcripts (not used in this study).
3. Calculate proteolytic peptides with N-glycan sites. The theoretical tryptic peptides were calculated from the protein sequences. Cleavage was set to occur after arginine and lysine if next amino acid is not proline. In one peptide two miscleavages were set to be possible. Sequences having N-glycosylation consensus site (26,27), NXS/T/C, where X is not P, were stored.
Match peptides to spectra
The glycopeptide spectra were matched to the theoretical peptide fragments and the best scoring peptide sequences were listed. To limit the number of input peptides for each spectrum it was required that the spectrum contains a peptide+HexNAc peak.
All peaks with a relative intensity higher than 3% were considered as potential peptide+HexNAc peak. All peptides with mass matching those peaks with a tolerance of 50 mDa or 100 ppm were included. Theoretical fragment spectra contained b-and y-ion series without attached glycan.
Mass tolerance of fragment matches was either 50 mDa or 100 ppm and relative intensity limit was 0.5 % from the base peak.
Predict glycan compositions.
The mass of unknown glycan was expected to match the mass difference between measured glycopeptide precursor mass and the masses of best scoring peptides. List of possible glycan compositions, which match those mass differences, were generated with a mass tolerance of 200 mDa. The monosaccharides used in the glycan composition calculations were hexose (Hex), N-acetylhexosamine (HexNAc), sialic acid (NeuAc) and deoxyhexose (DeoxyHex). The accepted range of number of monosaccharide units was for Hex 3-15, HexNAc 2-15, NeuAc 0-4 and DeoxyHex 0-2. Also composition was allowed to have 0-3 formylations (CO). Some compositions were filtered out with the following rules (13): a) the number of deoxyhexoses plus 1 must be less than or equal to the sum of the number of hexoses and N-acetylhexosamines, and b) if there are no N-acetylhexosamines except in Nglycan core, then the number of sialic acids is zero.
Match glycopeptide compositions to spectra. First a fragment library of glycan
compositions was generated by in silico glycosidic cleavages. Then the glycan compositions from glycopeptides observed after MS analysis were scored against the theoretical fragments.
Some impossible fragments were filtered out (i) if they did not fulfill the requirement of the Nglycan core, (ii) if NeuAc residues were assumed to attach to the N-glycan core HexNAcs or the branching hexose or (iii) if NeuAc and DeoxyHex residues were connected to each other.
The peptide backbones were assumed to stay intact. The spectrum peaks matching the peptide fragments without glycan were filtered out before composition matching. Mass tolerances for fragment matching were 50 mDa or 80 ppm and relative intensity limit 0.75 %. The final glycopeptide score (in Supplementary Table 8 ) was a sum of peptide score and glycan composition scores.
Filter by decoy matches. Statistical validation of peptide hits was done based on a targetdecoy approach (28).
The main assumption is that the false positive hits (random spectra) are independent and have an equal probability to match target or decoy databases. Decoy database was generated by reversing target peptides i.e. the human peptides having the N-glycosylation site. The peptide identification, glycan composition and composition matching steps were done exactly the same way against the target and the decoy peptide databases. After that, for each spectrum, it was compared which one gives higher score and thus identifies target or decoy matches. The score parameter used was the peptide score of highest ranked glycopeptide after glycopeptide composition scoring step. By assuming independent experiments, the number of false positive hits to target database can be estimated from the number of hits to decoy database by inverting the binomial distribution (Huttlin et al. 2007 ). The score cut off was selected so that the expected (mean) ratio of true positive hits to the target database was 90%. With the sample of purified serotransferrin it was possible to verify the expected true positive rate (Supplement 
Scoring method
Score to a theoretical glycopeptide G is calculated as a negative logarithm of a probability that a random set of fragments would have as many or more shared peaks with measured spectrum as the ranked glycopeptide. , where i ∈ {1... N } and j ∈ {1... M }. The probability P R that the random spectrum R have more or equal shared peaks than the glycopeptide spectrum G,
where Nh =SPC (G,S) and Mp M = p .
Finally the score values are given as Score(G,S)=-log(P R ).
It should be noted that the definition of the score used here is not supposed to reflect the true probability of a match being false positive. Simply because molecule fragments are composed by atoms they are not distributed evenly and no true random peaks exists. Despite that this simple approximation works well in practical cases to differentiate good hits from bad ones. The score defined here resembles the Ascore which has been used with phosphorylation site determination (Beausoleil; Villén et al. 2006) . Figures   Figure 1. The glycoprotein analysis flow. After the wet lab and LC-MS 2 work all the consecutive analysis were performed in the Medicel Integrator software platform and with automated workflow (marked with gray background). From the original 10 000 spectra, 300 glycoprotein spectra were extracted to the Integrator platform. First putative peptide interpretations were made and scored for all spectra, then the same spectra were analysed for their putative glyco compositions and finally the observed peaks in the spectra representing the glycan together with the amino acid sequences were matched and scored against theoretical peaks. of a given glycopeptide, liberation of its glycans and their analysis against the theoretical fragments generated from the published glycan structure. We got the same glyco structures with both the traditional, laborious and non-high-throughput wet lab techniques as with our novel automated in silico workflow. Tables   Table 1 Identified human serotransferrin glycopeptides The interpretations of the 62 glycopeptide spectra from the human serotransferrin sample. Only the best amino acid sequences and the best glycan compositions are shown for each spectra. The estimated true positive rate of peptide hits is 90 %. There is no statistical validation or score cut off for glycan composition (gp score), but in general the confidence of identification increases with score. A more detailed representation of the data, with putative glycan structures are given in Supplementary 
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